👉 The DISCLOSE Act Fails

In a new podcast, Sirota talks with Dr. Aaron Kesselheim, the Harvard researcher who last month touched off national headlines when he resigned from a panel that advises the Food and Drug Administration on drug approvals.

Kesselheim quit because the agency approved a pharmaceutical company's unproven Alzheimer's treatment, even though the panel of overseers was nearly unanimous in finding that the therapy had not displayed compelling evidence that it worked.

In a co-authored New York Times op-ed, Kesselheim warned that "in recent years, under steady pressure from the pharmaceutical industry and the patient groups it funds, the FDA has progressively lowered its standards of effectiveness and safety required for drug approvals."

This podcast is exclusively for Daily Poster paying subscribers.

If you are already a subscriber, but still see a “This post is for subscribers only” notice in the online version of this post, click here to log in to this website and you will be able to access the podcast player (instructions for logging in are here).

Only paid subscribers can comment. Please subscribe or sign in to join the conversation.